Hepatocellular carcinoma (HCC) remains a leading cause of cancer-related mortality worldwide, particularly in regions with ...
Hepatocellular carcinoma (HCC) is the most common subtype of primary liver cancer and continues to be a major cause of cancer ...
Verastem Oncology , a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced the grant of stock options to purchase 73,000 ...
Hosted on MSN
Oh no! Bo Nickal vs. Yoel Romero yanked from RAF 05 event after last-second weight miss
Bo Nickal will not be competing later tonight (Sat., Jan. 10, 2026) at RAF 05 from inside Amerant Bank Arena in Sunrise, Fla., following an unexpected weight miss by 48-year-old Yoel Romero. On Friday ...
Immuneering Corporation stays a Strong Buy: pancreatic cancer combo shows 64% 12‑mo OS, strong safety, and clear catalysts through 2028. Click for this IMRX update.
- Reported 12-month overall survival (OS) in Phase 2a clinical trial nearly double the benchmark from pivotal study of standard of care gemcitabine/nab-paclitaxel ...
SOUTH SAN FRANCISCO - BridgeBio Oncology Therapeutics (NASDAQ:BBOT) announced Wednesday preliminary safety and efficacy data from three clinical-stage programs targeting RAS-pathway malignancies. The ...
Tumor-infiltrating microorganisms have been presented as an unappreciated component of the tumor microenvironment, but there are few examples of their influence on tumor phenotypes or response to ...
Tumor-infiltrating microorganisms have been presented as an unappreciated component of the tumor microenvironment, but there are few examples of their influence on tumor phenotypes or response to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results